Autoimmune hepatitis

John Edison Prieto Ortiz, MD,1 Javier Preciado, MD,2 Sandra Huertas Pacheco, MD.3

Abstract
Autoimmune hepatitis is a condition which can be asymptomatic or can present as acute hepatitis or liver cirrhosis. Diagnosis is based on clinical criteria and laboratory criteria. Laboratory criteria include elevated levels of immunoglobulin G and/or autoantibodies and histological criteria such as hepatitis interface, the presence of plasma cells and lymphocytic infiltrate. In difficult to diagnose cases original or modified scoring systems can be used. Treatment is based on the use of immunosuppressants such as corticosteroids and azathioprine that have changed the natural history of disease.

Key words
Autoimmune hepatitis, acute hepatitis, cirrhosis, hepatitis interface, scoring systems, steroids.

DEFINITION
Autoimmune hepatitis (AIH) was first described in 1950, but has been known since by different names including active chronic hepatitis, aggressive chronic hepatitis, lupoid hepatitis, plasmatic cell hepatitis and more commonly, autoimmune chronic active hepatitis. In 1992, the International Autoimmune Hepatitis Group recommended that autoimmune hepatitis was the most appropriate term for this disease (1). AIH is defined as a generally persistent or unresolved chronic hepatitis of unknown origin (2).

EPIDEMIOLOGY
This disease is present in all races and in all geographic areas of the world (2, 3). As with other autoimmune diseases, the average initial age of appearance is around forty years of age but can vary and may appear from the first year of life until eighty years of age. Among children, the mean age for appearance of type 1 autoimmune hepatitis is between 10 and 11 years of age while it is between 6 and 7 years of age for type 2 AIH (3-6). Women are affected more frequently than men with a female to male ratio of 3.6:1 (7).

In the USA there are no clear epidemiological data, but, in Norway and Sweden the mean incidence is 1 to 2 for every 100,000 people per year and its prevalence is from 11 to 17 per 100,000 people per year. Similar incidence and prevalence are assumed for North America's Caucasian population. However, due to the subclinical nature of the disease in an important proportion of patients, it is possible that these numbers are greater (8, 9).

NATURAL HISTORY
The natural evolution of the untreated disease is known as the result of experiences published before the use of immunosuppressive drugs for AIH became generalized and before the detection of hepatitis C (HCV). These studies showed that 40% of the patients with severe untreated disease died within 6 months of diagnosis and that the survivors frequently developed cirrhosis with esophageal varicose veins and subsequent hemorrhaging (10-15).
tation of the disease was common (40%) and sometimes present together with severe acute hepatic insufficiency with hepatic encephalopathy developing within 8 weeks of the clinical symptoms (16-19). Approximately 30% of cases were completely asymptomatic and insidious form while another 30% began as cirrhotic. The possibility of cirrhosis could be predicted by the histological findings. 17% of the patients had developed interface hepatitis at 5 years, 49% developed mild to moderate alterations within 15 years, 82% developed bridging (or multilobular) cirrhosis. Of these the 5 year mortality rate was 44% (10, 12).

Three randomized treatment controlled clinical trials have established that prednisone alone or in combination with azathioprine improves symptoms, laboratory test results, histological results and immediate survival rates (11-13). These studies led to the acceptance of immuno-suppressive regimes as standard treatment and supported an autoimmune pathogenesis of the disease.

Liver transplantation has also evolved as efficient treatment for patients with decompensated cirrhosis, and the 5 year graft and patient survival rates now exceed 80% (20-23).

**PATHOGENESIS AND GENETICS**

The exact pathogenesis of autoimmune hepatitis is unknown although molecular mimicry is considered to be the generator of autoimmunity. One theory postulates that environmental triggers cause the loss of mechanisms for immune tolerance in genetically predisposed patients which induces an immunological attack mediated by T-cells on liver antigens which leads to progressive necroinflammation and fibrosis (24).

While the exact relation between genes and the autoimmune process has not been defined, it is believed that the antigen, the major histocompatibility complex (MHC) and the T-cell receptor (TCR) are involved at the molecular level in which small segments called complementary determinant regions (CDR) identify and contact the MHC complex.

Viruses, medications, herbs and vaccines have been suggested as triggering agents, but the nature of the antigen is still unclear. In most cases, no specific inducer of autoimmunity has been identified. The measles virus, hepatitis virus, simple herpes virus, varicella zoster virus, cytomegalovirus and Epstein-Barr virus and medications such as oxyphenisatin, methyldopa, nitrofurantoin, diclofenac, minocycline and possibly statins have all been implicated as initiators of the disease (11). The administration of interferon may mask or induce autoimmunity and the treatment of chronic viral hepatitis with alpha interferon may induce or unmask autoimmune hepatitis (12).

Most of the evidence supports the central role of an alteration of the T-cell function in the pathogenesis of AIH, and anomalies in B cells may also be important. With loss of tolerance an escape of normal suppression occurs in the auto-reactivity of T-cells which results in inflammation and necrosis (24-27).

In Caucasians, classic AIH (type 1) is strongly associated with the HLA-DR3 and HLA-DR4 serotypes. DRB1 * 0301 and DRB3 3 0101 are common genotypes in North America and DRB1 * 1301 is the most common in South America. There is an association of Type 2 AIH with HLA-DRB1 * 07, HLA-DRB1*03 and DQB1 * 0201 alleles. In Japan, where HLA-DR3 occurs infrequently, there is a primary association with the HLA-DR4 serotype (DRB1 * 0405 and DQB1 * 0401 genotypes) (25-27).

**CLINICAL**

AIH’s very broad clinical spectrum ranges from asymptomatic patients to those with a wide variety of symptoms. Symptoms include asthenia adynamia, malaise, anorexia, nausea, abdominal pain and pruritus. Patients with acute liver insufficiency present jaundice and coagulopathy.

Asymptomatic patients may be identified with routine exams where the only evidence of liver disease may be elevated transaminases. On other occasions the asymptomatic patient is discovered during abdominal surgery for various causes. At the other extreme of the spectrum are patients who present the acute form, sometimes with acute liver insufficiency, severe jaundice, prolonged coagulation and transaminase values greater than 1000 U/L (1, 2, 4). These patients may or may not have developed cirrhosis (Figure 1).

Physical examination can show normal features or it can show the presence of hepatomegaly, splenomegaly, stigmas of chronic liver disease and jaundice (1, 2, 4).

AIH may be associated with other autoimmune diseases including Sjögren syndrome, Crest, SLE, hemolytic anemia, idiopathic thrombocytopenic purpura, diabetes mellitus, hypothyroidism, thyroiditis, celiac disease, ulcerative colitis, and vitiligo. One prospective study found concurrent immunological diseases present in 38 percent of 122 patients with autoimmune hepatitis while only 22 percent of 63 patients with chronic viral hepatitis had concurrent immunological diseases (30).

Because up to 70% of asymptomatic patients become symptomatic during the course of the disease, asymptomatic patients must be monitored throughout their entire lives to supervise changes in the disease's activity (28, 29).

**DIAGNOSIS**

The 2010 guidelines of the American Association for the Study of Liver diseases suggest the following considerations (4):

- Diagnosis must be based on clinical examination of patients, laboratory and histological tests including abnormal results of liver biochemical exams, increased total IgG or gamma-globulin levels, serological markers (ANA, SMA, anti-LKM-1 or anti-LC1), and interface hepatitis (Figure 2).

- Other conditions that may cause chronic hepatitis must be excluded.

- The standard grading system must be used for evaluation of unclear cases.

- For cases which are negative for conventional antibodies, additional antibodies must be found. Minimally they must include atypical anti-SLA and pANCA.

- Cholangiography must be considered to exclude primary sclerosing cholangitis in adults who do not respond to corticosteroid treatment within three months.

- In children, cholangiography must be considered to exclude sclerosing autoimmune cholangitis.

- All patients with autoimmune hepatitis or inflammatory intestinal disease must be submitted to cholangiography to exclude primary sclerosing cholangitis.

**LABORATORY TESTS**

Laboratory tests must include the usual liver function evaluations of aminotransferases (ALT and AST), gamma glutamyl transferase (GGT), alkaline phosphate (AP), total and differential proteins, bilirubin (conjugated and non-conjugated), serum immunoglobulin G (IgG) and protein electrophoresis.

As a general rule, elevation of transaminase levels is more striking in autoimmune hepatitis than are elevated levels of bilirubin and alkaline phosphatase. In some cases however, autoimmune hepatitis has the appearance of cholestasis (28-29).

Characteristic laboratory results for AIH are elevated levels of serum globulins, especially gamma globulins and IgG (Figure 1). Hyperglobulinemia is generally associated with circulating antibodies which are particularly useful for identifying autoimmune hepatitis (31).

**Autoantibodies**, while not specific for AIH, identify patients with autoimmune hepatitis, allow classification, and indicate appropriate treatment. Since their expression varies throughout the course of the disease, it is believed that they are not involved in the entity’s pathogenesis (32-37). Consequently, a low small titer for autoantibodies does not exclude a diagnosis of autoimmune hepatitis while a high titer, in the absence of other findings, do not confirm an AIH diagnosis (38). Titer measurement in adults does, however, correlate with the severity of the disease, clinical course and approximate response to treatment. In the pediatric population of patients under 18 years of age, titer measurement is a useful biomarker for the disease’s activity and may be used to monitor treatment response (34-36).

**Antinuclear antibodies** (ANAs) are the most common antibodies circulating in autoimmune hepatitis. They are observed in adults and children with type 1 AIH, but rarely in type 2 AIH. When the titer is considered positive depends partially on the methodology used and the age of the
A liver biopsy is recommended at the start of any study to establish the diagnosis and guide treatment decisions (2, 4, 12, 38, 49). Autoimmune hepatitis is histologically characterized by the following non-specific findings (45):

- Portal lymphoplasmacytic infiltrate with occasional eosinophils
- Interface hepatitis or invasion of the lymphoplasmacytic portal infiltrate into the plaque that surrounds the portal triad extending up to the lobule (periportal infiltrate)
- Occasional lobular commitment sometimes with centrilobular necrosis.
- Changes in the bile duct (destructive or non-destructive cholangitis and ductopenia) present in approximately 25% of the patients.
- Granulomas are rarely seen
- Plasmatic cell infiltrates, hepatocyte rosettes and giant multinucleated cells.

Fibrosis is present in all forms of autoimmune hepatitis, even in the mildest cases. The degree may vary from very mild to advanced. Fibrosis appears with bridging, distortion of the architecture and appearance of regeneration nodules which result in cirrhosis (46).

Histological results vary according to the evolution of the disease. Compared to patients with slow starting disease (48), patients with severe acute liver insufficiency show more interface hepatitis, lobular hepatitis, lobular disorder, hepatocyte necrosis, central less than massive necrosis, but they suffer less fibrosis and cirrhosis (47, 48).

Histological findings, including frequency of cirrhosis, are similar for both symptomatic and asymptomatic patients (45) (Figure 3).

CLASSIFICATION

Type 1 and type 2 of AIH have been recognized on the basis of serological markers (32-44) but have not been established as valid clinical or pathological entities. A third type (type 3) was proposed but has been abandoned because its serological marker (anti-SLA) is also found in 10% to 30% of type 1 and 2 AIH patients (42-43).

Type 1 (classic AIH) is characterized by the presence of ANAS and/or SMA. It constitutes 80% of all IH cases. 75% of these patients are female and peak incidence occurs among patients between 16 and 30 years old. 50% of the patients are older than 30 and 23% are older than 60. Associations with other autoimmune diseases are common (15-34%). At the time of diagnosis cirrhosis is present in 25% of these patients (2, 4, 38-40, 45).

Type 2 AIH is characterized by the presence of anti-LKM1 and/or anti-LC1. The majority of patients with type 2 autoimmune hepatitis are children whose serum levels of immunoglobulins are generally elevated. The diseases
tends to be more aggressive and cirrhosis is found in up to half of the patients at the time of the diagnosis even though a severe acute form may also be present (2, 4, 5, 40, 43, 44).

**SCORING SYSTEMS**

**Original scoring system:** Diagnostic criteria for autoimmune hepatitis for the original scoring system were developed by an international panel in 1993 as an investigation tool to standardize population studies and clinical trials (1). They were reviewed in 1999 (50) (Table 1). This system assigned scores to different laboratory and histology elements. The system can be applied before and after treatment. A pretreatment score of 10 points or more, or a score of 12 points or more after treatment, indicates “possible AIH”. A score of 10 points before the treatment has a sensitivity of 100%, a specificity of 73% and diagnostic precision of 67%. A pretreatment score of 15 points, “defined AIH” has a sensitivity of 95%, a specificity of 97% and diagnostic precision of 94% (51). The clinical criteria are sufficient for diagnosing AIH as definitive or probable in most patients. The diagnostic score system may be applied in difficult cases (50).

**Simplified scoring system:** In 2008 a system was developed with simplified criteria based on four determinations: titers of antibodies, levels of IgG, hepatic histology and exclusion of viral hepatitis (52). A probable diagnosis of autoimmune hepatitis is established with a total of 6 points and a definitive diagnosis is established with a total of 7 or more points.

A validation study conducted at 11 participating international medical centers found that the simplified scoring system with a cutoff of six of more points had 88% sensitivity and 99% specificity when a cutoff point of seven or greater is used (53). A later study with a cutoff point of seven or greater showed slightly lower sensitivity of 70%, but specificity remained high at 100% (54). The simplified version of the scoring system shows a high sensitivity and specificity in the diagnosis of autoimmune hepatitis but still has not been validated in prospective studies (Table 2) (52-55).

**DIFFERENTIAL DIAGNOSIS**

Because of the wide range of AIH characteristics mentioned which include age, appearance, clinical manifestations, and presentation in both genders, the entity must be considered in the differential diagnosis of any patient with evidence of acute or chronic liver disease (Figure 4) (2-4, 6, 38).

**TREATMENT**

The initial studies of glucocorticoid therapy (GCT) for AIH showed the benefit of the treatment for severe patients and justified the use of immunosuppressives (11-13). It is known that adequate management improves quality of life, prolongs patient survival and delays the need for liver transplantation. Since cases with less serious biochemical or histological clinical indications have not been studied sufficiently to determine treatment, there are not always indications for treatment when we diagnose autoimmune hepatitis (2, 4, 7, 22, 56). The decision to treat must be individualized based on:

- The severity of the symptoms
- The degree of serum aminotransferase and IgG elevation
- Histological findings and
- The possibility of secondary effects.

<table>
<thead>
<tr>
<th>Category</th>
<th>Factor</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Female</td>
<td>+2</td>
</tr>
<tr>
<td>FAL/GOT (or GPT) ratio</td>
<td>&gt; 3</td>
<td>-2</td>
</tr>
<tr>
<td></td>
<td>&lt; 1,5</td>
<td>+2</td>
</tr>
<tr>
<td>Gammaglobulina o IgG (times over normal upper limit)</td>
<td>&gt; 2,0</td>
<td>+3</td>
</tr>
<tr>
<td></td>
<td>1,5-2,0</td>
<td>+2</td>
</tr>
<tr>
<td></td>
<td>1,0-1,5</td>
<td>+1</td>
</tr>
<tr>
<td></td>
<td>&lt; 1,0</td>
<td>0</td>
</tr>
<tr>
<td>Tities of ANA, SMA, or anti-LKMI</td>
<td>&gt; 1:80</td>
<td>+3</td>
</tr>
<tr>
<td></td>
<td>1:80</td>
<td>+2</td>
</tr>
<tr>
<td></td>
<td>1:40</td>
<td>+1</td>
</tr>
<tr>
<td></td>
<td>&lt; 1:40</td>
<td>0</td>
</tr>
<tr>
<td>AMA</td>
<td>Positive</td>
<td>+4</td>
</tr>
<tr>
<td>Viral markers of active infection</td>
<td>Positive</td>
<td>-3</td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>+3</td>
</tr>
<tr>
<td>Hepatotoxic drugs</td>
<td>Yes</td>
<td>-4</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>+1</td>
</tr>
<tr>
<td>Alcohol</td>
<td>&lt; 25 g/d</td>
<td>+2</td>
</tr>
<tr>
<td></td>
<td>&gt; 60 g/d</td>
<td>-2</td>
</tr>
<tr>
<td>Concurrent autoimmune disease</td>
<td>Any non-hepatic disease with immune origin</td>
<td>+2</td>
</tr>
<tr>
<td>Others autoantibodies</td>
<td>Anti-SLA/LP, actine, LCI, pANCA</td>
<td>+2</td>
</tr>
<tr>
<td>Histologic characteristics</td>
<td>Interphase</td>
<td>+3</td>
</tr>
<tr>
<td></td>
<td>Plasmatic cells</td>
<td>+1</td>
</tr>
<tr>
<td></td>
<td>Rosets</td>
<td>+1</td>
</tr>
<tr>
<td></td>
<td>None of the above</td>
<td>-5</td>
</tr>
<tr>
<td></td>
<td>Biliary changes</td>
<td>-3</td>
</tr>
<tr>
<td></td>
<td>Atypical features</td>
<td>-3</td>
</tr>
<tr>
<td>HLA</td>
<td>DR3 o DR4</td>
<td>+1</td>
</tr>
<tr>
<td>Treatment response</td>
<td>Complete remission</td>
<td>+2</td>
</tr>
<tr>
<td></td>
<td>Remission with relapse</td>
<td>+3</td>
</tr>
</tbody>
</table>

Pretreatment score

<table>
<thead>
<tr>
<th>Pretreatment score</th>
<th>Definitive diagnosis</th>
<th>&gt; 15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Probable diagnosis</td>
<td>10-15</td>
</tr>
</tbody>
</table>

Posttreatment score

<table>
<thead>
<tr>
<th>Posttreatment score</th>
<th>Definitive diagnosis</th>
<th>&gt; 17</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Probable diagnosis</td>
<td>12-17</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Type 1 AIH</th>
<th>Value Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANA o AML +</td>
<td>≥ 1:40</td>
</tr>
<tr>
<td>ANA o AML +</td>
<td>≥ 1:80</td>
</tr>
<tr>
<td>Anti LKM +</td>
<td>≥ 1:40</td>
</tr>
<tr>
<td>Anti SLA + Positive</td>
<td>+ 2</td>
</tr>
<tr>
<td>IgG Upper normal limit</td>
<td>+ 1</td>
</tr>
<tr>
<td></td>
<td>&gt; 1,1 normal limit</td>
</tr>
<tr>
<td>Histology Compatible</td>
<td>+ 1</td>
</tr>
<tr>
<td></td>
<td>Typical</td>
</tr>
<tr>
<td>Absence of viral hepatitis</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>No</td>
</tr>
</tbody>
</table>

> 6 points: Probable autoimmune hepatitis
< 7 points: Definitive autoimmune hepatitis
Maximum value per antibodies: 2 points


AASLD guidelines (4) establish:

**Absolute indications**

1. AST of at least 10 times the upper limit of the normal range.
2. AST more than five times the normal upper limit, along with a gamma-globulin serum level more than twice the upper normal limit.
3. Histological findings of bridging necrosis or multilobular necrosis
4. Incapacitating symptoms associated with hepatic inflammation, such as fatigue and arthralgia, independent of other severe disease indexes.

**Uncertain indications for treatment**

Treatment decisions for asymptomatic adults with slight laboratory and histological indications must be individualized and balanced according to treatment risks. The AASLD recommends referral of these patients to a hepatologist.

**Treatment counter indications**

1. Inactive cirrhosis
2. Minimum or no disease activity; these patients must be monitored every three to six months.
3. Patients with severe preexisting diseases or comorbidity conditions (vertebral conditions, psychosis, osteoporosis, diabetes or uncontrolled hypertension) or a previously known intolerance to prednisone, unless the disease is severe and progressive. Appropriate measures to comorbidities may be taken.
4. Patients with severe pretreatment cytopenia (white blood cell count below 2,500 or platelet count under 50,000 or a known complete deficiency of thiopurine methyltransferase.)

**Treatment schemes**

Treatment schemes are based on the use of glucocorticoids monotherapy or combination therapy with steroid sparing agents such as azathioprine which aim at decreasing adverse effects of glucocorticoids. These two schemes have not been directly compared in controlled clinical trials with long-term follow-ups, but data and clinical experience suggest similar efficiencies (2, 4, 56-61).

- Prednisone alone (60 mg a day)
- Lowest dose of prednisone (30 mg a day), along with azathioprine (50 mg used in the USA or 1-2 mg/kg of body weight in Europe) (Table 1).

Prednisone can be decreased to a low enough level to maintain remission. After 20 mg a day doses should be reduced 5 mg/week until a 10 mg/day dosage is reached. Greater reductions should be 2.5 mg/week until 5 mg/day is reached (4).

Combined treatment is appropriate for patients who will be treated continuously for at least 6 months or who are at great risk of complications related to corticoids. Once the maintenance dose is reached, it must be continued until disease resolution, treatment failure, or medication intolerance. There is no minimum or maximum treatment duration. Duration is individualized according to the result, desired response and tolerance (2, 4, 56-61) (Figure 5).

<table>
<thead>
<tr>
<th>TREATMENT SCHEMES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisone alone (mg/d)</td>
</tr>
<tr>
<td>Prednisone (mg/d)</td>
</tr>
<tr>
<td>Week 1</td>
</tr>
<tr>
<td>Week 2</td>
</tr>
<tr>
<td>Week 3</td>
</tr>
<tr>
<td>Week 4</td>
</tr>
<tr>
<td>Maintenance</td>
</tr>
</tbody>
</table>

**REASONS FOR CHOOSING A REGIME**

- Cytopenia
- TMT deficiency
- Pregnancy
- Malignancy
- Short course under 6 months
- Postmenopause
- Osteoporosis
- Discompensated DM
- Acné obesity
- HTA

**Figure 5.** Treatment schemes in autoimmune hepatitis, adapted from de Manns MP, Czaja AJ, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193(4).

**Remission or resolution of the disease**

Remission or resolution of the disease is the ideal treatment goal. It is characterized by normalization of laboratory alterations in AST, ALT, gamma-globulin, IgG serum levels and histology. This goal is reached in 10% to 40% of patients (2, 4, 56-61). 90% of adults show improvement in AST, bilirubin, and levels of gamma-globulin by two weeks after the start of treatment (62). Histological improvement occurs three to eight months after clinical and laboratory improvement (12, 47-49). Adults rarely resolve their histological anomalies in less than 12 months and the probability of remission during the treatment decreases after 2 years. Achievement of normal laboratory values before the treatment’s completion decreases relative relapse risk after drug are discontinued by three to eleven times the risk for patients who do not achieve this result (47-79). In a study, 87% of the patients that achieved long-term remission had normalized the laboratory indexes before completion of treatment (63).

It is recommended that patients be maintained on fixed daily maintenance doses until remission achieved since
early attempts to adjust the dose according to the clinical response could delay or prevent histological improvement. Daily treatment rather than treatment on alternate days or steroid pulses is recommended because alternate day treatment may improve symptoms and laboratory results without providing histological resolution (63).

Termination of treatment must be considered after two years if liver function and immunoglobulin levels repeatedly test normal. A liver biopsy prior to termination of treatment is the only method to assure full resolution of the disease (48, 49, 56-63).

Treatment failure

Approximately 10% of patients experience clinical and laboratory deterioration despite conventional treatment (4). Failure is characterized by sustained inflammatory activity leading to the development or worsening of cirrhosis with eventual complications and death, or the need for a liver transplant. Failure occurs more frequently in three groups of patients (22):

- People with established cirrhosis
- People who develop the disease at an early age or have had a longer duration of the disease before treatment.
- Those who possess the HLA-B8 allele and/or HLA-DR3 phenotypes.

Optimum treatment of the persistent disease is not well established. The AASLD suggests therapy with 60 mg of prednisone a day and 150 mg/day of azathioprine for at least one month after which the prednisone dose is decreased by 10 mg, and the dose of azathioprine is decreased by 50 mg after each month of clinical improvement until the conventional maintenance doses are reached (4). 70% of the patients improve their clinical and laboratory results within 2 years and survival is preserved. Histological remission is achieved for only 20% of these patients. The majority of patients remain in therapy and at risk of secondary effects of the medication and/or the disease’s progression (63, 64).

Incomplete response

Patients with incomplete responses improve clinically, present improved laboratory test results and histological indexes, but do not experience complete resolution. They account for approximately 13% of the patients after 36 months of treatment (59-63). Alternative treatment strategies must be considered. These include long-term low doses of corticosteroids with a gradual decrease of the prednisone dose of 2.5mg a month until the lowest level (10mg a day) is reached with normal AST or ALT. Another alternative is 2 mg/kg/day of azathioprine for people who do not tolerate corticosteroids and require more treatment (59-63).

Medication toxicity

The toxicity of the drug for 10% to 13% of patients justifies premature interruption or alteration of conventional therapy for these patients. In these cases, therapy with the tolerated agent must be kept at an adjusted dose (59-63).

Secondary effects related to treatment

Corticosteroids

- Esthetic effects produced in 80% of patients after 2 years of treatment with corticosteroids include a moon face, dorsal hump, striations, weight gain, acne, alopecia and facial hirsutism (65-66).
- The most severe systemic effects include osteopenia with vertebral compression, diabetes, psychosis, pancreatitis, opportunistic infections, arterial hypertension and malignancy. In general, they occur after prolonged treatment (4-60, 65, 66).

Azathioprine

Cytopenia is the main secondary effect related to azathioprine, and its most severe consequence is bone marrow failure (65). Cytopenia’s frequency among AIH patients treated with azathioprine is 46% with a 6% chance of severe hematologic anomaly (68). Patients under azathioprine treatment must have a leukocyte and platelet recount every 6 months (65). Other complications of azathioprine treatment for AIH include cholestatic hepatitis, pancreatitis, nausea, vomiting, rashes, opportunistic infections, and malignancy (65). The incidence of extrahepatic neoplasia in treated autoimmune hepatitis is 1/194 patients/year and the probability of a tumor is 3% after 3 years (67).

Additional adverse effects must be fully explained to patients before treatment.

Additional measures

Additional measures to reduce adverse effects of medications must be introduced according to the individual perception of risk (2, 4, 5, 11, 12, 13).

Prednisone

For patients treated with prednisone, periodical ophthalmological assessments to evaluate cataracts and glaucoma are necessary. Also, prevention of osteoporosis is important. Basal densitometry and annual lumbar spine and hip checkups are a requirement. In addition patients need regu-
lar exercise programs, vitamin D and calcium supplements and/or active agents for the bones such as bisphosphonates (63, 65, 66).

**Azathioprine**

At any dosage the patient must be monitored for leucopenia and thrombocytopenia at 6 month intervals (2, 4, 5, 58-61).

As in other hepatopathies, patients with AIH who present negative viral markers must be vaccinated for hepatitis B (HBV) and hepatitis A (HAV) ideally before therapy (2, 4, 58-61).

**Treatment alternatives**

Few patient series have been published about the use of medications such as cyclosporine, tacrolimus, methotrexate, mycophenolate mofetil, and budesonide to treat patients who are refractory or intolerant to azathioprine and/or 6-MP (64, 69-73). No medications used in empirical rescue therapies have been incorporated into any standard management algorithm. Mycophenolate mofetil is currently the most promising drug. The AASLD also suggests its use in oral doses of 2g per day (4, 64, 65, 69). At this dosage it has shown improvements in 39% to 84% of patients who tolerate mycophenolate. Nevertheless, 34% to 78% of these patients suspend the medication due to intolerance (nausea, vomiting, pancreatitis, rash, alopecia, deep vein thrombosis, diarrhea and lack of normalization of hepatic function tests (69, 74).

**AIH treatment for children**

The evolution of the disease in children seems to be more severe than in adults perhaps due to delays in diagnosis or to other concurrent autoimmune diseases such as sclerosing cholangitis (2, 4, 5). Since more than 50% of these children have cirrhosis at the beginning, the milder parts of the disease described in adults are not typically seen in children. This makes medication therapy justified at the time of diagnosis (2, 4, 5, 57-61). Prednisone is the fundamental pillar in all children’s schemes. It is initially administered in a 1-2mg/kg/day dosages (up to 60mg a day) due to the significant long term harmful effects of high or intermediate corticoid doses during initial growth and development of bones and physical appearance. The early use of 1 to 2mg/kg/day of azathioprine or 1.5mg/kg/day of 6-mercaptopurine is recommended for all children who do not have contraindications (2, 4, 5, 57-61).

**Cirrhosis treatment for active AIH**

Patients who have cirrhosis have a greater frequency of complications related to medications than do those without cirrhosis (25% vs. 8%) (2, 4, 11-13). They must be thoroughly monitored during treatment, and those with cytopenia must be evaluated for the activity of thiopurine methyltransferase before administration of azathioprine (2, 4, 11-13, 11, 65, 66, 68, 75). The response may be excellent, even in those that have experienced bleeding from esophageal varices or who have serious ascites. There is even the possibility of reversion of the cirrhosis (76). Many patients respond when treatment starts, and the 10 year survival rate for treated patients, including those with cirrhosis, exceeds 90% (4, 61, 66, 75).

**AIH treatment during pregnancy**

Glucocorticoids and azathioprine are probably safe during pregnancy. However, azathioprine is in FDA category D for pregnant women because it has been associated with congenital malformations in pregnant rats and because low levels of 6-thioguanine nucleotides are detectable in newborns whose mothers have been treated for Crohn’s disease (75, 77-79). Even though no increases of birth defects have been detected in children of mothers who received this treatment, and even though there have been no evident negative consequences from breastfeeding by treated mothers, caution is justified when using azathioprine during pregnancy (4, 75, 79). Pregnancy among women with autoimmune hepatitis has been associated with a greater risk of prematurity, low birth weight and fetal death. Patients must be carefully monitored during pregnancy and for several months after birth due to the risk of outbreaks of the disease’s activity. While estrogen levels in the blood drop, conventional therapy must be resumed in a preventive manner two weeks before birth and continued postpartum (4, 63, 64, 75, 79).

**HEPATOCELLULAR CARCINOMA**

Hepatocellular carcinoma develops in 4% of type 1 AIH patients. The probability this neoplasia developing within 10 years is 2.9% (81). In North America the risk of hepatocellular carcinoma is related to males, portal vein hypertension (ascites, varicose veins or thrombocytopenia), and immunosuppressive treatment for at least 3 years and to cirrhosis of at least 10 years duration (80).

A monitoring strategy based on hepatic echography at 6 month intervals is recommended for these individuals (82).

**AUTOIMMUNE HEPATITIS TRANSPLANT**

AIH is an indication for liver transplantation (LT) in approximately 2% to 3% of pediatric patients and 4% to 6% of adult patients in the United States of America and Europe.
LT is indicated for patients with acute liver failure. It is the treatment of choice for patients who progress to decompensated cirrhosis with a MELD score greater than or equal to 15 and for those with hepatocellular carcinoma that meet the criteria for a transplant (85-87). Untreated patients have a 10 year survival rate of less than 30% (20-22). Failed treatment that requires LT is often associated with HLA DRB1 * 0301 genotypes (88). Transplant for AIH has good results, with 5 to 10 year survival rates of approximately 75% (4, 85-87). Prior characteristics of patients do not seem to influence these transplant results or the recurrence of AIH (89).

REFERENCES

24. Donaldson PT. Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol 2004; 41: 327.
63. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-1012.


89. Dbouk N, Parekh S. Impact of pre-transplant Anti-nuclear antibody (ANA) and Anti-smooth muscle antibody (SMA) titers on disease recurrence and graft survival following liver transplantation in autoimmune hepatitis (AIH) patients. J Gastroenterol Hepatol 2012; 1440-1746.